<p>ADC Therapeutics SA（纽约证券交易所代码：ADCT - 获取免费报告）目前获得了五位分析师一致评定为 “适度买入”，MarketBeat 报道称。其中一位研究分析师给予该股票卖出评级，四位分析师则给予买入评级。在过去一年中，给予该股票评级的经纪人平均 12 个月目标价格为 7.3333 美元。</p>
<p>获取 <strong>ADC Therapeutics</strong> 的提醒：</p>
<p>ADCT 最近成为多份研究报告的主题。华尔街禅在 11 月 15 日的报告中将 ADC Therapeutics 的评级从 “卖出” 上调至 “持有”。加拿大皇家银行在 12 月 3 日的研究报告中重申了 “跑赢大盘” 的评级，并对 ADC Therapeutics 的股票设定了 5.00 美元的目标价格。Weiss Ratings 在 1 月 21 日的报告中重申了 ADC Therapeutics 的 “卖出（d-）” 评级。最后，Guggenheim 在 11 月 12 日的研究报告中重申了 “买入” 评级，并设定了 10.00 美元的目标价格。</p>
<p><strong>查看我们对 ADCT 的最新分析</strong></p>
<h2>ADC Therapeutics 的机构交易</h2>
<p>一些机构投资者和对冲基金最近买入和卖出了该股票的股份。Engineers Gate Manager LP 在第四季度新建了对 ADC Therapeutics 的持仓，价值约 43,000 美元。AQR Capital Management LLC 在第四季度将其在 ADC Therapeutics 的持仓提高了 42.2%。AQR Capital Management LLC 目前拥有 206,576 股该公司股票，价值 729,000 美元，此前在上个季度增持了 61,324 股。Cantor Fitzgerald L. P. 在第四季度新建了对 ADC Therapeutics 的持仓，价值约 353,000 美元。Jump Financial LLC 在第四季度将其在 ADC Therapeutics 的持仓提高了 1,299.8%。Jump Financial LLC 目前拥有 162,250 股该公司股票，价值 573,000 美元，此前增持了 150,659 股。最后，Price T Rowe Associates Inc. MD 在第四季度将其在 ADC Therapeutics 的持仓提高了 25.6%。Price T Rowe Associates Inc. MD 目前拥有 46,750 股该公司股票，价值 166,000 美元，此前增持了 9,537 股。目前 41.10% 的股票由机构投资者和对冲基金持有。</p>
<h2>ADC Therapeutics 股票表现</h2>
<p>纽约证券交易所 ADCT 周三开盘价为 4.07 美元。该公司的 50 日移动平均价格为 3.82 美元，200 日移动平均价格为 3.83 美元。该股票的市值为 5.0444 亿美元，市盈率为-2.81，贝塔值为 1.92。ADC Therapeutics 的 52 周低点为 1.05 美元，52 周高点为 4.80 美元。</p>
<h2>ADC Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>ADC Therapeutics SA 是一家临床阶段的生物制药公司，专注于高度靶向抗体药物偶联物（ADCs）的发现和开发，旨在治疗如非霍奇金淋巴瘤和急性髓性白血病等血液恶性肿瘤。通过将单克隆抗体的特异性与强效细胞毒性药物结合，该公司旨在最大限度地消灭肿瘤细胞，同时限制非靶向毒性。</p>
<p>ADC Therapeutics 组合的核心是 loncastuximab tesirine-lpyl，这是一种针对 CD19 的 ADC，已获得美国的加速批准。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 ADC Therapeutics</li>
<li>新发现的富铜 “克拉肯” 区</li>
<li>白银是新的石油——而世界正在枯竭</li>
<li>美国的 1776 再次发生</li>
<li>你可能想更换财务顾问的三个迹象</li>
<li>白银的挤压正在收紧——机会正在形成</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFEQ1Q?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFEQ1Q"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 ADC Therapeutics 吗？</h2>
<p>在你考虑 ADC Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 ADC Therapeutics 并不在名单上。</p>
<p>虽然 ADC Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IBBQ

医疗业 ETF - SPDR

ADCT

<p>ADC Therapeutics SA（纽约证券交易所代码：ADCT）获得了五位分析师的 “适度买入” 共识评级，其中一位给予卖出评级，四位给予买入评级。12 个月的平均目标价为 7.33 美元。最近的报告包括华尔街 Zen 将评级上调至 “持有”，以及 Guggenheim 设定 10 美元的目标价。机构投资者持有该股票的 41.10%。ADC Therapeutics 专注于开发针对血液恶性肿瘤的抗体药物偶联物，市值为 5.0444 亿美元，目前股价为 4.07 美元</p>

<p>ADC Therapeutics SA (NYSE:ADCT - Get Free Report) has been given a consensus rating of &#34;Moderate Buy&#34; by the five analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $7.3333.</p>
<div class="lb-trans"><p>ADC Therapeutics SA（纽约证券交易所代码：ADCT - 获取免费报告）目前获得了五位分析师一致评定为 “适度买入”，MarketBeat 报道称。其中一位研究分析师给予该股票卖出评级，四位分析师则给予买入评级。在过去一年中，给予该股票评级的经纪人平均 12 个月目标价格为 7.3333 美元。</p>
</div><p>Get <strong>ADC Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>ADC Therapeutics</strong> 的提醒：</p>
</div><p>ADCT has been the subject of a number of recent research reports. Wall Street Zen raised ADC Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 15th. Royal Bank Of Canada reaffirmed an &#34;outperform&#34; rating and issued a $5.00 price objective on shares of ADC Therapeutics in a research note on Wednesday, December 3rd. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of ADC Therapeutics in a report on Wednesday, January 21st. Finally, Guggenheim reiterated a &#34;buy&#34; rating and set a $10.00 target price on shares of ADC Therapeutics in a research report on Wednesday, November 12th.</p>
<div class="lb-trans"><p>ADCT 最近成为多份研究报告的主题。华尔街禅在 11 月 15 日的报告中将 ADC Therapeutics 的评级从 “卖出” 上调至 “持有”。加拿大皇家银行在 12 月 3 日的研究报告中重申了 “跑赢大盘” 的评级，并对 ADC Therapeutics 的股票设定了 5.00 美元的目标价格。Weiss Ratings 在 1 月 21 日的报告中重申了 ADC Therapeutics 的 “卖出（d-）” 评级。最后，Guggenheim 在 11 月 12 日的研究报告中重申了 “买入” 评级，并设定了 10.00 美元的目标价格。</p>
</div><p><strong>Check Out Our Latest Analysis on ADCT</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ADCT 的最新分析</strong></p>
</div><h2>Institutional Trading of ADC Therapeutics</h2>
<div class="lb-trans"><h2>ADC Therapeutics 的机构交易</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Engineers Gate Manager LP acquired a new position in ADC Therapeutics during the 4th quarter worth about $43,000. AQR Capital Management LLC raised its position in shares of ADC Therapeutics by 42.2% during the fourth quarter. AQR Capital Management LLC now owns 206,576 shares of the company's stock worth $729,000 after acquiring an additional 61,324 shares during the last quarter. Cantor Fitzgerald L. P. bought a new position in shares of ADC Therapeutics during the fourth quarter worth about $353,000. Jump Financial LLC lifted its stake in shares of ADC Therapeutics by 1,299.8% in the fourth quarter. Jump Financial LLC now owns 162,250 shares of the company's stock worth $573,000 after acquiring an additional 150,659 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in ADC Therapeutics by 25.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,750 shares of the company's stock valued at $166,000 after acquiring an additional 9,537 shares during the last quarter. 41.10% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近买入和卖出了该股票的股份。Engineers Gate Manager LP 在第四季度新建了对 ADC Therapeutics 的持仓，价值约 43,000 美元。AQR Capital Management LLC 在第四季度将其在 ADC Therapeutics 的持仓提高了 42.2%。AQR Capital Management LLC 目前拥有 206,576 股该公司股票，价值 729,000 美元，此前在上个季度增持了 61,324 股。Cantor Fitzgerald L. P. 在第四季度新建了对 ADC Therapeutics 的持仓，价值约 353,000 美元。Jump Financial LLC 在第四季度将其在 ADC Therapeutics 的持仓提高了 1,299.8%。Jump Financial LLC 目前拥有 162,250 股该公司股票，价值 573,000 美元，此前增持了 150,659 股。最后，Price T Rowe Associates Inc. MD 在第四季度将其在 ADC Therapeutics 的持仓提高了 25.6%。Price T Rowe Associates Inc. MD 目前拥有 46,750 股该公司股票，价值 166,000 美元，此前增持了 9,537 股。目前 41.10% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>ADC Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>ADC Therapeutics 股票表现</h2>
</div><p>NYSE ADCT opened at $4.07 on Wednesday. The firm's fifty day moving average price is $3.82 and its two-hundred day moving average price is $3.83. The stock has a market cap of $504.44 million, a PE ratio of -2.81 and a beta of 1.92. ADC Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $4.80.</p>
<div class="lb-trans"><p>纽约证券交易所 ADCT 周三开盘价为 4.07 美元。该公司的 50 日移动平均价格为 3.82 美元，200 日移动平均价格为 3.83 美元。该股票的市值为 5.0444 亿美元，市盈率为-2.81，贝塔值为 1.92。ADC Therapeutics 的 52 周低点为 1.05 美元，52 周高点为 4.80 美元。</p>
</div><h2>ADC Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>ADC Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.</p>
<div class="lb-trans"><p>ADC Therapeutics SA 是一家临床阶段的生物制药公司，专注于高度靶向抗体药物偶联物（ADCs）的发现和开发，旨在治疗如非霍奇金淋巴瘤和急性髓性白血病等血液恶性肿瘤。通过将单克隆抗体的特异性与强效细胞毒性药物结合，该公司旨在最大限度地消灭肿瘤细胞，同时限制非靶向毒性。</p>
</div><p>At the core of ADC Therapeutics' portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>ADC Therapeutics 组合的核心是 loncastuximab tesirine-lpyl，这是一种针对 CD19 的 ADC，已获得美国的加速批准。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than ADC Therapeutics</li>
<li>New Copper-Rich “Kraken” Zone Discovered</li>
<li>Silver Is the New Oil—And the World’s Running Dry</li>
<li>America’s 1776 happening again</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>Silver's squeeze is tightening - opportunity forming</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 ADC Therapeutics</li>
<li>新发现的富铜 “克拉肯” 区</li>
<li>白银是新的石油——而世界正在枯竭</li>
<li>美国的 1776 再次发生</li>
<li>你可能想更换财务顾问的三个迹象</li>
<li>白银的挤压正在收紧——机会正在形成</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFEQ1Q" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=ADCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ADC Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 ADC Therapeutics 吗？</h2>
</div><p>Before you consider ADC Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 ADC Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADC Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 ADC Therapeutics 并不在名单上。</p>
</div><p>While ADC Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ADC Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of "Moderate Buy" from Brokerages

Market Beat

Invesco Nasdaq Biotechnology ETF

ADC Therapeutics SA

2 倍做多纳斯达克生物技术 ETF - ProShares

标普全球医疗股指数 ETF - iShares

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

基因改革 ETF - ARK

医疗业 ETF - Vanguard

纳斯达克生物科技指数 ETF - iShares Nasdaq

ADC Therapeutics SA（NYSE:ADCT）被券商给予 “适度买入” 的平均评级